JP7641910B2 - Ｐｄ－１と結合する抗体 - Google Patents

Ｐｄ－１と結合する抗体 Download PDF

Info

Publication number
JP7641910B2
JP7641910B2 JP2021560586A JP2021560586A JP7641910B2 JP 7641910 B2 JP7641910 B2 JP 7641910B2 JP 2021560586 A JP2021560586 A JP 2021560586A JP 2021560586 A JP2021560586 A JP 2021560586A JP 7641910 B2 JP7641910 B2 JP 7641910B2
Authority
JP
Japan
Prior art keywords
antibody
seq
amino acid
fragment
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021560586A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022538375A (ja
JP2022538375A5 (enExample
Inventor
ユエ，ハイタオ
リン，ジアン
ペイ，シュジュン
リアン，シゾン
リ，シェンフェン
Original Assignee
バイオ － テラ ソリューションズ、リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイオ － テラ ソリューションズ、リミテッド filed Critical バイオ － テラ ソリューションズ、リミテッド
Publication of JP2022538375A publication Critical patent/JP2022538375A/ja
Publication of JP2022538375A5 publication Critical patent/JP2022538375A5/ja
Application granted granted Critical
Publication of JP7641910B2 publication Critical patent/JP7641910B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70521—CD28, CD152
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70532—B7 molecules, e.g. CD80, CD86

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Hospice & Palliative Care (AREA)
JP2021560586A 2019-04-10 2020-04-09 Ｐｄ－１と結合する抗体 Active JP7641910B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201910286677 2019-04-10
CN201910286677.9 2019-04-10
PCT/CN2020/083954 WO2020207432A1 (en) 2019-04-10 2020-04-09 Antibody Binding to PD-1

Publications (3)

Publication Number Publication Date
JP2022538375A JP2022538375A (ja) 2022-09-02
JP2022538375A5 JP2022538375A5 (enExample) 2024-10-09
JP7641910B2 true JP7641910B2 (ja) 2025-03-07

Family

ID=72750942

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021560586A Active JP7641910B2 (ja) 2019-04-10 2020-04-09 Ｐｄ－１と結合する抗体

Country Status (7)

Country Link
US (1) US12466887B2 (enExample)
EP (1) EP3931223A4 (enExample)
JP (1) JP7641910B2 (enExample)
CN (2) CN117603355A (enExample)
AR (1) AR118619A1 (enExample)
TW (1) TWI916327B (enExample)
WO (1) WO2020207432A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022007807A1 (zh) * 2020-07-07 2022-01-13 百奥泰生物制药股份有限公司 双特异性抗体及其应用
CN116437926B (zh) * 2020-10-11 2026-01-20 百奥泰生物制药股份有限公司 抗pd-1抗体在联合用药中的应用
EP4353746A4 (en) * 2021-06-11 2024-12-04 Guangdong Fapon Biopharma Inc. Anti-pd-1 humanized antibody or antigen-binding fragment thereof and application thereof
WO2025140324A1 (zh) 2023-12-26 2025-07-03 百奥泰生物制药股份有限公司 抗pd-1抗体联合化疗剂在治疗肿瘤中的用途
WO2025190251A1 (zh) * 2024-03-12 2025-09-18 百奥泰生物制药股份有限公司 抗trop2抗体药物偶联物和pd-1拮抗剂联合治疗实体瘤的用途
CN120919340A (zh) * 2024-05-09 2025-11-11 百奥泰生物制药股份有限公司 抗FRα抗体药物偶联物和PD-1拮抗剂在治疗肿瘤中的应用
CN121015902A (zh) * 2024-05-27 2025-11-28 百奥泰生物制药股份有限公司 抗trop2抗体药物偶联物和抗pd-l1/cd47双特异抗体联合治疗肿瘤的用途
CN121754666A (zh) * 2024-09-30 2026-03-31 百奥泰生物制药股份有限公司 一种抗pd-1抗体制剂及其制备方法和用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010530753A (ja) 2007-06-18 2010-09-16 エン． フェー． オルガノン ヒトのプログラムされたデスレセプターｐｄ−１に対する抗体

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6699658B1 (en) * 1996-05-31 2004-03-02 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
PL3368572T5 (pl) 2015-10-02 2026-07-20 Les Laboratoires Servier Przeciwciała anty-PD-1 oraz kompozycje
EP3604539A4 (en) * 2017-03-27 2020-12-23 National University Corporation Hokkaido University ANTI-PD-L1 ANTIBODY FOR DETECTION OF PD-L1
WO2018217227A1 (en) * 2017-05-24 2018-11-29 Immunomedics, Inc. Novel anti-pd-1 checkpoint inhibitor antibodies that block binding of pd-l1 to pd-1
CN108997499B (zh) * 2018-09-12 2020-07-31 首都医科大学附属北京胸科医院 一种抗人pd-l1抗体及其应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010530753A (ja) 2007-06-18 2010-09-16 エン． フェー． オルガノン ヒトのプログラムされたデスレセプターｐｄ−１に対する抗体

Also Published As

Publication number Publication date
EP3931223A1 (en) 2022-01-05
EP3931223A4 (en) 2023-07-12
US12466887B2 (en) 2025-11-11
TW202104262A (zh) 2021-02-01
CN111808190A (zh) 2020-10-23
US20220204623A1 (en) 2022-06-30
AR118619A1 (es) 2021-10-20
CN111808190B (zh) 2023-12-12
CN117603355A (zh) 2024-02-27
WO2020207432A1 (en) 2020-10-15
TWI916327B (zh) 2026-03-01
JP2022538375A (ja) 2022-09-02

Similar Documents

Publication Publication Date Title
US20240018257A1 (en) Antibodies specific to human poliovirus receptor (pvr)
TWI916327B (zh) 結合pd-1的抗體
KR102629403B1 (ko) Vista 항원 결합 분자
TWI754800B (zh) 新型抗ox40/pd-l1雙特異性抗體分子、新型抗vegf/gitr雙特異性抗體分子及其用途
TWI858393B (zh) 介白素２突變體以及其融合蛋白
CN114901691A (zh) Ilt3结合剂及其使用方法
JP7860978B2 (ja) 二重特異性抗体及びその応用
US20230183342A1 (en) Antibodies to nkp46 and constructs thereof for treatment of cancers and infections
CA3203257A1 (en) Anti-b7-h3 antibody and uses thereof
TWI883241B (zh) 抗pd-l1抗體及其應用
WO2023236991A1 (zh) 靶向her2，pd-l1和vegf的三特异性抗体
HK40033623B (en) Antibody binding to pd-1
CN120230216B (zh) 抗lair1抗体及其用途
HK40033623A (en) Antibody binding to pd-1
CN121108346B (zh) 抗ly6g6d单域抗体及其制备方法和用途
US20250144178A1 (en) Pharmaceutical composition for cancer treatment comprising fusion protein including il-12 and anti-fap antibody and anticancer agent
WO2024153163A1 (zh) 抗cd93抗体及其应用
WO2025140497A1 (zh) Pvrig结合蛋白、双特异性抗体及其应用
HK40123044B (en) Pharmaceutical combination and use
HK40123044A (zh) 药物组合及用途
EP4737479A1 (en) 4-1bb-binding protein
CN121758625A (zh) 靶向pd-1和4-1bb的双特异性抗体及其应用
KR20240051277A (ko) PD-L1, CD137, 및/또는 TGFβ에 대한 이중특이체 및 삼중특이체 결합 단백질 및 이의 용도
HK40090273A (en) Antibodies to nkp46 and constructs thereof for treatment of cancers and infections

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230327

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240510

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240702

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20241001

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250204

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250225

R150 Certificate of patent or registration of utility model

Ref document number: 7641910

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150